Asieris Receives NMPA's IND Approval to Evaluate APL-1202 + Tislelizumab as Neoadjuvant Therapy for MIBC Patients
Shots:
- NMPA’s CDE has approved the IND application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients with muscle invasive bladder cancer. The US FDA has cleared the IND of the therapy in Jun’2021
- The P-I/II study will evaluate the safety in MIBC patients- to determine RP2D and to assess efficacy as neoadjuvant therapy for MIBC
- APL-1202 is an orally available reversible MetAP2 Inhibitor with anti-angiogenic- anti-tumor activities and can also modulate tumor immune microenvironment
| Ref: PR Newswire | Image: Asieris
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com